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Gradual but definite progress has been made in the treat-
ment of younger adults with acute myeloid leukaemia
(AML) [1–3], except those 25–30% with high-risk disease.
For them the best approach is a myeloablative allogeneic
transplant; however, even the transplant option provides
only a 30% chance of cure, and has been limited to younger
patients who have a donor. The point at which a patient is
recognised to be at high risk is usually after the first course
of induction treatment has been given when the most useful
prognostic data is to hand.
These patients represent an important unmet therapeutic
need for which there is no specific standard of care. The
challenge is three-fold. First, for those who will go forward
to transplant improving the pre-transplant chemotherapy
could reduce the post-transplant relapse rate. Second, better
treatment could deliver more patients to transplant who
otherwise might relapse before reaching transplant. Third,
better treatment is needed for patients for whom a transplant
is not available.
For relapsed patients the FLAG-Ida (fludarabine/cytosine
arabinoside (ara-C)/granulocyte-colony stimulating factor
(G-CSF) and idarubicin) is widely used, although it has not
been subjected to a randomised assessment. In our Medical
Research Council (MRC) AML15 Trial, FLAG-Ida given
for the first two treatment courses had a significantly
superior anti-leukaemia effect [4]. It therefore appeared
logical to continue with FLAG-Ida as consolidation for
patients who were identified as high risk. We chose as the
comparative treatment to replace ara-C, in a daunorubicin/
ara-C combination, with an alternative nucleoside, clofar-
abine, which has demonstrated activity in adverse risk
patients [5–9]. Following a successful feasibility study
combining daunorubicin with clofarabine, we decided to
prospectively compare this combination with FLAG-Ida in
high-risk patients.
The AML17 protocol (ISRCTN55675535) was designed
to include untreated de novo or secondary AML and high-
risk myelodysplastic syndrome (defined as >10% marrow
blasts at diagnosis). The overall treatment plan has been
described elsewhere [10] and was conducted in accordance
with the Declaration of Helsinki, sponsored by the Cardiff
University, and approved by the Wales Research Ethics
Committee 3. The age range was between 16 and 61 years,
although older patients were permitted if deemed suitable
for the potential randomisations. Three hundred and eleven
patients were randomised after having received the first
induction course, which could have been ADE (Ara-C/
daunorubicin/etoposide) alone (N= 39) or with gemtuzu-
mab ozogamicin (GO) 3 mg/m2 (n= 29) or 6 mg/m2 (n=
30) or daunorubicin/Ara-C (DA) with GO 3mg/m2 (N=
35) or 6 mg/m2 (N= 22) with the daunorubicin dose being
60 mg/m2 (n= 78) or 90 mg/m2 (n= 78). GO was given on
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Table 1 Patient characteristics and outcomes
DClo FLAG-Ida OR/HR, 95% CI p Value
Number randomised 207 104
Age group (years)
15–29 (16%) 6 (3%) 7 (7%)
30–39 (20%) 17 (8%) 8 (8%)
40–49 (19%) 29 (14%) 14 (13%)
50–59 (29%) 95 (46%) 46 (44%)
60+ (37%) 60 (29%) 29 (28%)
Gender
Female 66 (32%) 35 (34%)
Male 141 (68%) 69 (66%)
Type of disease
De novo 147 (71%) 74 (71%)
Secondary 38 (18%) 20 (19%)
High-risk MDS 22 (11%) 10 (10%)
Performance status
0 149 (72%) 75 (72%)
1 50 (24%) 24 (23%)
2 5 (2%) 2 (2%)
3 3 (1%) 3 (3%)
4 0 0
Induction treatment
ADE (NR) 11 (5%) 6 (6%)
ADE 14 (7%) 8 (8%)
ADE+GO3 20 (10%) 9 (9%)
ADE+GO6 20 (10%) 10 (10%)
DA+GO3 23 (11%) 12 (12%)
DA+GO6 15 (7%) 7 (7%)
DA60 52 (25%) 26 (25%)
DA90 52 (25%) 26 (25%)
Cytogenetics
Favourable 0 0
Intermediate 102 (49%) 49 (47%)
Adverse 105 (51%) 55 (53%)
NK 0 0
FLT3-ITD
WT 195 (94%) 96 (92%)
Mutant 4 (2%) 1 (1%)
Not known 8 (4%) 7 (7%)
NPM1
WT 173 (84%) 87 (84%)
Mutant 25 (12%) 9 (9%)
Not known 9 (4%) 8 (8%)
MRD status post C1
−ve 21 (10%) 8 (8%)
+ve 43 (21%) 16 (15%)
Not in CR 65 (31%) 31 (30%)
Not known 78 (38%) 49 (47%)
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day 1. The patients were designated as high risk by our
validated weighted score (based on cytogenetics, gender,
white count, secondary disease, older age, and failure to
achieve at least a reduction in marrow blasts to <15%, or to
50% of blasts at diagnosis) [11, 12]. Consenting patients
were randomised (2:1) to receive up to three courses of
DClo (daunorubicin 50 mg/m2 on days 1, 3 and 5 and
clofarabine 20 mg/m2 days 1–5) or FLAG-Ida (fludarabine
30 mg/m2 days 2–6, ara-C 2 g/m2 days 2–6, G-CSF 263 µg
days 1–7, idarubicin 8 mg/m2 days 4–6) with the intention
of going to allogeneic transplant if feasible. The end points
of interest were the number of patients delivered to trans-
plant and overall survival (OS) whether transplanted or not.
Toxicity (haematologic recovery times and non-
haematologic toxicity) were scored using National Cancer
Institute Common Toxicity Criteria, version 3 and resource
use was collected. All end points were defined according to
the revised International Working Group Criteria [13]
With 315 patients, the trial had 80% power to detect an
improvement in survival from 30 to 45%, and an
improvement in the number of patients receiving a trans-
plant from 40 to 57%.
All analyses are by intention to treat. Categorical end
points (e.g. complete remission (CR) rates) were compared
using Mantel-Haenszel tests, giving Peto odds ratios (ORs)
and confidence intervals. Continuous/scale variables were
analysed by non-parametric (Wilcoxon's rank-sum) tests.
Time-to-event outcomes were analysed using the log-rank
test, with Kaplan–Meier survival curves. ORs/hazard ratios
(OR/HRs) <1 indicate benefit for DClo. Survival percen-
tages are at 5 years except for patients censored at transplant
which is at 4 years. Median follow-up is 47.4 months (range
3.1–74.7 months). In addition to overall analyses, explora-
tory analyses were performed stratified by the randomisa-
tion stratification parameters and other important variables,
with suitable tests for interaction. Because of the well-
known dangers of subgroup analysis, these were interpreted
cautiously.
Between September 2009 and October 2012, of 1583
patients in the AML17 Trial, 468 (30%) became eligible for
the high-risk intervention, of whom 311 patients (66%)
entered the randomisation in whom the OS was 31% at 5
years, which was not significantly different from the 157
eligible, but un-randomised, patients (25%; p= 0.18). The
characteristics and responses are shown in Table 1. The
proportion of FLT3-mutated patients is low because such
patients entered the lestaurtinib randomisation in the trial
[10]. Eighty-nine patients (29%) were >60 years. Minimal/
Table 1 (continued)
DClo FLAG-Ida OR/HR, 95% CI p Value
MRD status post C2
CR/CRi, MRD −ve 20 (11%) 12 (13%) MRD −ve vs. MRD +ve vs. no
CR, p= 0.08
CR/CRi, MRD +ve 29 (15%) 18 (20%)
CR/CRi, MRD unk 93 (49%) 49 (53%)
Not in CR 47 (25%) 13 (14%)
Not known 18 12
ORR (CR+ Cri) 83% 86% 1.24 (0.66–2.34) 0.5
CR 68% 72% 1.23 (0.74–2.05) 0.4
CRi 15% 13%
30-day mortality 2% 4% 0.61 (0.15–2.45) 0.5
60-day mortality 9% 10% 0.95 (0.44–2.06) 0.9
5-year OS 26% 44% 1.40 (1.05–1.86) 0.02
4-year OS censored at
SCT
15% 28% 1.27 (0.87–1.85) 0.2
5-year CIR 51% 39% 1.38 (0.95–2.01) 0.09
5-year CIDCR 24% 17% 1.45 (0.83–2.51) 0.19
5-year RFS 25% 44% 1.40 (1.03–1.91) 0.03
Number within parentheses indicates the percentage of non-APL patients in each age group who entered the high-risk randomisation expressed as a
proportion of all patients entering the AML17 Trial
CR complete remission, APL acute promyelocytic leukaemia, AML acute myeloid leukaemia, FLT3 fms-like tyrosine kinase 3, ITD internal tandem
duplication, MRD minimal/measurable residual disease, CRi complete remission with incomplete count recovery, NPM1 nucleophosmin member
1, NK natural killer,WT wild type, OR odds ratio, CI confidence interval, OS overall survival, ORR overall response ratio, SCT stem cell transplant,
CIR cumulative incidence of relapse, MDS myelodysplastic syndrome, CIDCR cumulative incidence of death in remission, RFS relapse-free
survival
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measurable residual disease (MRD) information, as pre-
viously defined [14], was available in 88 patients. There
was a significant trend towards increasing high risk with
age. One hundred and sixty-nine patients (54%) were
already in CR or complete remission with incomplete count
recovery (CRi) (DClo 54%; FLAG-Ida 55%) and a further
52 had confirmed CR/CRi after first course (representing
32% of DClo patients not known to be in remission at
randomisation, and 47% of FLAG-Ida patients). Seventeen
percent of DClo and 14% of FLAG-Ida had resistant dis-
ease. In the DClo arm, the number of courses given was—0:
1%; 1: 38%; 2: 47%; 3: 14%, and in the FLAG-Ida arm was
—1: 56%; 2: 38%; 3: 6%.
Overall 175 (56%) received a transplant and was not
different between the arms (DClo 58%: FLAG-Ida 53%)
(OR 0.83 (0.52–1.34), p= 0.4). For DClo 74 received a
matched myeloablative transplant (20 siblings, 54 MUDs)
and FLAG-Ida 33 (15 siblings, 18 MUDs). Reduced
intensity allografts were given to 37 (14 siblings, 23 MUDs)
in the DClo arm, and 12 (3 siblings, 9 MUDs) in the FLAG-
Ida arm. There were an additional 31 transplants reported of
other or unknown type (DClo 21, FLAG-Ida 10), giving an
overall transplant rate of 120/207 (58%) vs. 55/104 (53%)
(OR 0.81 (0.51–1.31), p= 0.4).
The cumulative incidence of relapse (CIR), relapse-free
survival (RFS) and OS at 5 years for DClo vs. FLAG-Ida
were 51 vs. 39% (HR 1.38 (0.95–2.01), p= 0.09); 25 vs.
44% (HR 1.40 (1.03–1.91), p= 0.03); and 26 vs. 44% (HR
1.40 (1.05–1.86), p= 0.02) (Table 1 and Fig. 1a–c). There
were no significant interactions between treatment effect
and age (p= 0.5) or cytogenetics (p= 0.3). When outcomes
are censored at the time of transplant, the effect estimate for
survival was similar (4-year survival 15 vs. 28%; HR 1.27
(0.87–1.85), p= 0.2) (Fig. 1d). However, RFS post trans-
plant in first remission was worse in patients receiving
transplant following DClo compared with following FLAG-
Ida (39 vs. 69%; HR 1.96 (1.19–3.21), p= 0.008).
FLAG-Ida was significantly more myelosuppressive than
DClo. Neutrophil recovery to 1.0 × 109/l was longer (40 vs.
32 days) (p= 0.005) as was platelets recovery to 100 × 109/l
(61 vs. 45 days) (p= 0.16), resulting in a greater require-
ment for red cells (10.7 vs. 6.9) and platelets (12.9 vs. 7.1),
days on antibiotics (19.3 vs. 10.6) and days in hospital
(median 31 vs. 23) (p < 0.0001 for each). The non-
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Fig. 1 Outcome data. a Overall survival, b relapse-free survival, c cumulative incidence of relapse and d survival censored at stem cell
transplantation
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haematological toxicities observed were similar after course
2 of treatment.
Minimal (measurable) residual disease was undertaken
by flow cytometry in a parallel lab study. The sensitivity
was 1 × 104 and the results were not conveyed to investi-
gators. There was no difference between the arms at ran-
domisation post course 1 of chemotherapy in the proportion
entering with or without MRD information/being MRD
+ve or MRD −ve. However, after the first course of ran-
domised treatment, significantly fewer DClo patients were
in confirmed morphological remission (75 vs. 86% of those
with data, p= 0.04), and there was evidence of worse MRD
response overall (p= 0.08), although the proportions of the
79 patients in CR with MRD information who were MRD
−ve was similar between arms (41 vs. 40%, p= 0.9).
In our previous experience, about 40% of high-risk
patients got to transplant, which resulted in an RFS of 39%.
Although FLAG-Ida is widely used in relapsed disease, it
has not been assessed by randomised comparison. Here 84%
of patients achieved CR or CRi as the best response with no
differences between the arms. Although FLAG-Ida did not
deliver more patients to allograft (43 vs. 48% with DClo),
OS was significantly better than with DClo, partly because
of the better RFS after transplant (69 vs. 39%). In patients
who were not already in remission on entering the rando-
misation FLAG-Ida did not deliver more patients to trans-
plant. Although the observations were limited, the response
by MRD status was not different between the arms.
We conclude that the FLAG-Ida was superior in high-
risk patients, despite not delivering more patients to trans-
plant. However, the resultant prolonged cytopenia can cause
unpredictable logistic difficulties in scheduling the trans-
plant, so checking the marrow status 10–14 days after the
chemotherapy and proceeding to transplant irrespective of
count recovery may be optimal. Survival also was sig-
nificantly better when transplant was not undertaken (44 vs.
28%), although there are likely to be major selection biases
in play in making such a comparison.
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